Drug intelligence / Profile preview

IBL-301

Development stage: Preclinical
Lead developer: Inflection Biosciences
Modality: Small Molecules
Administration: Intraperitoneal

Overview

IBL-301 is a preclinical multi-targeting kinase inhibitor being developed for oncology. It was licensed by Inflection Biosciences from the Spanish National Cancer Research Centre (CNIO) and is designed to inhibit the activity of PIM, PI3K, and mTOR kinases.

Targets

PI3K (Phosphoinositide-3-kinase regulatory subunit 6)mTOR (Mammalian target of rapamycin kinase)PIM1 (Proviral integration site for moloney murine leukemia virus kinase 1)

Beyond the preview

Go deeper on IBL-301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IBL-301.

Explore the full profile